
Durvalumab





ırvalumab DUO-E	
SCORE	
CURATIVE	
Overall Survival / Disease-Free Survival / Pathological Complete Response	
NON-CURATIVE	
Overall Survival	
Progression-Free Survival	
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate	
Overall Response Rate / Duration of Response	

Overall Survival / Disease-Free Survival / Pathological Complete Response

## INFORMATION

## Tumour type: Gynaecological Malignancies

Therapeutic Indication: FDA: Durvalumab is indicated with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). EMA: Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)

Experimental Arm: Durvalumab + Carboplatin and paclitaxel Control Arm: Carboplatin, paclitaxel, and placebo (arm A)



© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.